Genmab stock gains 5.32 percent on Rina-S data

Published on 10/05/2026 at 22:12 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Genmab stock reached DKK 2,377.00 on October 5 after Rina-S showed a 45.9 percent response rate in ovarian cancer. Guggenheim lifted its target to USD 54.

Aquarellmalerei des Kopenhagener Hafens mit bunten Häusern und Segelbooten am Kai — Genmab A/S Heimatstadt Kopenhagen als stimmungsvolles Aquarellgemälde mit Hafen und bunten Häusern, ISIN DK0010272202, Illustration mit AI erstellt.

Genmab stock (ISIN DK0010272202) closed at DKK 2,377.00 on October 5, 2026, gaining 5.32 percent as fresh Rina-S data strengthened the biotechnology companys pipeline story. According to Investing.com on October 5, the results came from Part C of the Phase 1/2 RAINFOL-01 study.

Rina-S delivers measurable response

Among 109 patients with platinum-resistant ovarian cancer, Rina-S achieved a confirmed objective response rate of 45.9 percent, including five complete responses. The median duration of response reached 12.1 months, while 51 percent of responders remained in remission at the one-year mark, Investing.com reported.

The activity was observed across all levels of folate receptor alpha expression, including patients with low or no expression. That result matters commercially because it points to a broader potential treatment population than a biomarker-restricted approach.

Pipeline value meets higher expectations

Guggenheim raised its Genmab price target to USD 54 from USD 45 on October 5 and maintained a Buy rating. The firm cited epcoritamab, petosemtamab and Rina-S, estimating that the programs could generate USD 8 billion in incremental near-term pipeline sales, according to Investing.com.

TradingView reported on October 2 that the average 12-month target stood at USD 39.56, up from USD 39.28, based on 20 analysts. Its broader consensus label was Buy across 26 analysts, with 24 Buy ratings, two Holds and zero Sells, while individual targets ranged from USD 31.33 to USD 50.

Genmab also raised its full-year 2026 revenue guidance to DKK 4.3 billion to DKK 4.5 billion, citing EPKINLY and DARZALEX performance, Investing.com reported. The companys next clinical readouts will test whether the valuation can keep pace with the expanding development program.

October 5 close marks a new high

Genmab shares closed at DKK 2,377.00 on Nasdaq Copenhagen on October 5, 2026, up 5.32 percent, according to Investing.com. An extraordinary general meeting is scheduled for October 7, 2026.